Crossmark

TIP60 enhances cisplatin resistance via regulating ΔNp63α acetylation in SCC

Published Online: 2024-12-03

Authors

Hira, Akshay

Zhang, Jin

Kadakia, Madhavi P. https://orcid.org/0000-0001-8890-268X
Funding

Funding for this research was provided by:

U.S. Department of Health & Human Services | NIH | National Cancer Institute (1R01CA280075, 1R01CA280075, 1R01CA280075)
License Information

Text and Data Mining valid from 2024-12-03

Version of Record valid from 2024-12-03
More Information

Article History

Received: 2 July 2024

Revised: 12 November 2024

Accepted: 26 November 2024

First Online: 3 December 2024

Competing interests

: The authors declare no competing interests.

: This study did not involve the use of human samples or data and no human participants were involved. As such, it meets the criteria for exemption from Institutional Review Board (IRB) approval or ethics review under 45 CFR 46.104(d). The research was conducted using cell lines provided under a Material Transfer Agreement (MTA). All necessary permissions and legal agreements regarding the use, transfer, and handling of the cell lines have been obtained in accordance with the terms outlined in the MTA. Protocols utilized in this study have been approved by the Institutional Biosafety Committee (IBC) under protocol IBC-00000057).

Document is current